;
(a) the details of the reasons given in the examination report of different
cost comparison of manufacturers of Dextroproxyphone and its salts;
(b) whether the Government has analyzed said reasons;
(c) if so, the details thereof;and
(d) the steps taken by the Government in this regard?
THE MINISTER OF CHEMICALS AND FERTILIZERS & MINISTER OF STEEL ( SHRI RAM VILAS PASWAN )
(a) to (d): The bulk drug Dextropropoxyphene (and its salts) is a Scheduled bulk drug under
Drugs (Prices Control) Order (DPCO), 1995. The comprehensive cost price study of this drug
was based on three manufacturers of this drug. According to the study, the producers are not
producing the drug from the same stage of production and consequently the costs of these
manufacturers were different.As per the guidelines of the National Pharmaceutical Pricing
Authority (NPPA) for pricing of bulk drugs, where more than one manufacturer produces a
product, the fair price determined for individual manufacturers is arranged in the ascending
order of prices.The fair price of the manufacturer at 2/3rd cut off level (considering 66.66% of
the production) of the total estimated production so worked out is compared with the weighted
average fair price of the units undertaken for the detailed cost study and the lower of the two, is
recommended as the fair price for the industry for that particular product.This practice is being
followed consistently for fixation of prices of bulk drugs where more than two manufacturers
produce the same drug.The price fixation of bulk drug Dextropropoxyphene and its salts is in
conformity with the practice followed in all such cases by NPPA without deviation.